MRK
Stock Details
MRK is Merck & Co., Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 88.19$. Average daily volumn in 3 months 8.16M. Market cap 223.92B
Stock symbol : MRK. Exchange : NYSE. Currency : USD Lastest price : 88.39$. Total volume : 5.87M. Market state POST Click reload if you want to check the lastest price on market!!!
Merck & Co., Inc. (MRK)
Last Price
88.39$Change
0.00Volume
5.87M
| Previous Close | 88.39 |
| Open | 88.58 |
| Day Range | 88.02-88.78 |
| Bid | 86.74 x 1k |
| Ask | 88.70 x 1k |
| Volume | 5.87M |
| Average Volume | 8.16M |
| Market Cap | 223.92B |
| Beta | 0.34 |
| 52 Week Range | 71.50-95.72 |
| Trailing P/E | 13.49 |
| Foward P/E | 11.88 |
| Dividend (Yield %) | 3.12% |
| Ex-Dividend Date | 2022-09-14 |
Financial Details
Organization
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuti... cals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Market Cap:
223.92BRevenue:
48.7BTotal Assets:
105.69BTotal Cash:
8.1B
News about "Merck & Co., Inc."
With Merck & Co., Inc. (NYSE:MRK) It Looks Like You'll Get What You Pay For
Source from : Yahoo Finance - 3 days ago
There wouldn't be many who think Merck & Co., Inc.'s (NYSE:MRK) price-to-earnings (or "P/E") ratio of 13.1x is worth a mention when the median P/E in the United States is similar at about 14x.See details»
Merck & Co. Inc. (MRK) is on the roll with an average volume of 8.37M in the recent 3 months
Source from : investchronicle - 2 days ago
Merck & Co. Inc. (MRK) is priced at $86.12 after the most recent trading session. At the very opening of the session, the stock price was $87.25 and reached a high price of $87.62, prior to closing ...See details»
Merck & Co., Inc. (NYSE:MRK) Price Target Increased to $110.00 by Analysts at SVB Leerink
Source from : Defense World - 4 days ago
Merck & Co., Inc. (NYSE:MRK – Get Rating) had its price objective lifted by SVB Leerink from $109.00 to $110.00 in a research note released on Friday morning, Stock Target Advisor reports. SVB Leerink ...See details»
Here’s Why You Should Consider Acquiring Merck (MRK) Shares
Source from : Yahoo - 12 days ago
Chartwell Investment Partners, an asset management company, released its second quarter 2022 investor letter. A copy of the same can be downloaded here. For the second quarter, Chartwell-managed ...See details»
What This News Means for Merck
Source from : The Motley Fool - 4 days ago
this would be $200 million in additional annual revenue for Merck. That's just a 0.4% bump over the average analyst forecast of $58.7 billion in 2022 revenue for the company. But pharma ...See details»
10 Analysts Have This to Say About Merck & Co
Source from : Business Insider - 5 days ago
According to 10 analyst offering 12-month price targets in the last 3 months, Merck & Co has an average price target of $101.5 with a high of $110.00 and a low of $88.00. Below is a summary of how ...See details»
Merck (MRK) Gains But Lags Market: What You Should Know
Source from : Zacks.com on MSN - 2 days ago
Merck (MRK) closed at $87.55 in the latest trading session, marking a +1.66% move from the prior day. This change lagged the S&P 500's 2.59% gain on the day. At the same time, the Dow added 2.66%, and ...See details»
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
Source from : Yahoo - 6 days ago
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on ...See details»
Merck's (MRK) Keytruda Gets Four New Approvals in Japan
Source from : Nasdaq - 7 days ago
Merck & Co., Inc. MRK announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for four new cancer ...See details»
Miracle Mile Advisors LLC Has $1.21 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)
Source from : Defense World - 10 days ago
Miracle Mile Advisors LLC lowered its stake in Merck & Co., Inc. (NYSE:MRK – Get Rating) by 2.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC.See details»
Pharmaceutical company spends $1 million to convert North Baton Rouge site to ear tag manufacturing plant
Source from : The Advocate - 1 days ago
A major international pharmaceutical company has spent more than $1 million to convert a North Baton Rouge veterinary medicine manufacturing facility into a plant that makes ear tags for cattle.See details»
AL Amyloidosis Pipeline Landscape Analysis of 10+ Companies by DelveInsight | Leading Players – Sanofi, Merck & Co, and Others
Source from : MarketWatch - 1 days ago
DelveInsight’s, “ AL Amyloidosis Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in AL Amyloidosis pipeline landscape. AL Amyloidosis ...See details»
Merck KGaA, Darmstadt, Germany, Partners with CNote to Invest $20 Million in Under-resourced Communities
Source from : Business Insider - 1 days ago
Investment will help expand access to capital, entrepreneurship and opportunity in U.S. locations where the company has significant ...See details»
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
Source from : MarketWatch - 6 days ago
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Court of Appeals ...See details»